PathToScale: The PERSIST Trial

This study is looking at how well long-acting injectable HIV prevention medicine (called cabotegravir, given as a shot every 2 months) works in real-world settings for people at higher risk of HIV. You may be eligible if: - You are 15 years or older - You are in one of the following groups considered at higher risk for HIV: - Female sex workers - Men who have sex with men - Transgender individuals - Women or young women seeking STI, family planning, or HIV testing services - Breastfeeding women - Male partners of female sex workers, or men at high risk of HIV, or men with a sexually transmitted infection You may NOT be eligible if: - You are already living with HIV or may be in the early stages of HIV infection - You have a history of hepatitis B - You have had a serious reaction to cabotegravir before - You are not able or willing to come back every 3 months for HIV testing and every 2 months for check-ins - You are currently taking medication for drug-resistant tuberculosis (MDR-TB) - You are currently on post-exposure HIV prevention medicine (PEP) Talk to your doctor to see if this trial is right for you.